Table 1: Clinical Trials of Stem Cells in Cardio-Vascular
Diseases
Sample Size |
Cell Type |
Study Design |
Delivery Route |
Outcome |
Ref |
Acute Myocardial
Infarction/Heart Failure |
|||||
0 |
Autologous mononuclear
bone marrow cells |
Catheter placed into the infarct-related
artery |
Intracoronary
transplantation |
myocardial regeneration
and neovascularisation |
[87] |
69 |
Autologous bone marrow mesenchymal stem cell |
|
Intracoronary injection |
Improvement in left
ventricular function |
[88] |
18 |
Autologous mononuclear
bone marrow cells |
|
Intracoronary
transplantation |
Functional and metabolic
regeneration of infracted and chronically vital tissue |
[89] |
25 |
BM-MNC |
|
Intramyocardial Injection |
Sustained beneficial
effect on anginal symptoms, myocardial perfusion,
and left ventricular function |
[90] |
46 |
Autologous of BMCs |
|
Intracoronary
transplantation |
Improves heart rate variability |
[91] |
15 |
Autologous Bone Marrow
mononuclear cells |
|
Injection into the
infarction border zone |
Decrease in heart failure
symptoms and an improved left ventricular (LV) function. |
[93] |
Sample Size |
Cell Type |
Study Design |
Delivery Route |
Outcome |
Ref |
Acute Myocardial Infarction/Heart Failure |
|||||
5 |
Autologous bone marrow derived MSC |
|
Intracoronary transplantation |
Slight improvement in myocardial function in 3 patients |
[92] |
32 |
Administration of BMCs |
|
Intracoronary infusion |
No change in LV ejection fraction could be demonstrated after repeated
|
[104] |
30 |
Autologous bone marrow cells |
|
Direct intramyocardial injection |
Improvement in symptoms achieved in approximately 50% of patients |
[94] |
30 |
Autologous mesenchymal SCs (MSCs) and (BMCs) |
Randomized, double-blind |
Intramyocardial
Injection |
Safety and efficacy (determined primarily by cardiac magnetic
resonance imaging) |
[105] |
53 |
Bone marrow-derived
allogeneic hMSCs |
Randomized, double-blind, placebo-controlled,
dose-escalation study |
Intravenous injection |
Intravenous
allogeneic hMSCs are safe in patients after acute
MI |
[106] |
20 |
Autologous bone
marrow mononuclear cell (ABMMNC) |
randomized study |
transendocardial injection |
ABMMNC therapy is
safe and improves symptoms, quality of life in patients with chronic HF |
[107] |
17 |
Bone marrow stem
cells (BMSCs) have been used to treat |
Randomized |
Intracoronary route |
The left ventricular
end-systolic volume (LVESV) and wall motion score index (WMSI), left
ventricular end-diastolic volume (LVEDV), LVESV, and WMSI were significantly
reduced in BMSC group |
[108] |
Sample Size |
Cell Type |
Study Design |
Delivery Route |
Outcome |
Ref |
Peripheral arterial disease |
|||||
45 |
Bone marrow-mononuclear
cells |
|
Injection into the
gastrocnemius of the ischaemic limb |
Significantly improved in legs |
[97] |
7 |
Autologous bone-marrow mononuclear cell |
|
Transplantation |
Improvement in endothelial dysfunction |
[98] |
28 |
G-CSF with mobilized PBMNCs |
Randomized study |
Subcutaneous injections of diabetic patients |
Lower limb pain and ulcers were significantly improved |
[109] |
1 |
Bone marrow mononuclear
cells |
|
Intramuscular and intraarterial injection |
Improvement chronic limb ischemia attributed to increased neo
angiogenesis |
[110] |
7 |
Autologous bone-marrow mononuclear cell |
|
Transplantation |
Improvement in endothelial dysfunction |
[98] |
28 |
G-CSF with mobilized PBMNCs |
Randomized study |
Subcutaneous injections of diabetic patients |
Lower limb pain and ulcers were significantly improved |
[109] |
1 |
Bone marrow mononuclear
cells |
|
Intramuscular, intraarterial injection |
Improvement chronic limb ischemia attributed to increased neo
angiogenesis |
[110] |
Sample Size |
Cell Type |
Study Design |
Delivery Route |
Outcome |
Ref |
Peripheral arterial disease |
|||||
12 |
Autologous bone-marrow mononuclear cell |
|
Transplantation |
Significant improvements in rest pain and pain-free walking time |
[99] |
140 |
BMCs with mobilized PBMNCs |
Randomized study |
Transplantation in the ischemic
necrosis |
Significant improvement, reduction in edema and increased colaateral vessels formation |
[111] |
32 |
Autologous bone-marrow mononuclear cell |
|
Intraarterial and intramuscular
injection |
Significant improvement in the lower limb ischemia |
[112] |
184 |
Bone marrow mononuclear
cells |
|
local injections |
Significantly enhanced endothelial colony-forming cell adhesion |
[113] |
40 |
Autologous (BM-MNC) |
Randomized study |
Injection |
Accelerates wound healing |
[101] |
527 |
Autologous (BM-MNC) |
Randomized study |
Injection |
Significant improvement in the amputation rate, ulcer healing, |
[114] |
Sample Size |
Cell Type |
Study Design |
Delivery Route |
Outcome |
Ref |
Patient with Breast cancer |
|||||
30 |
HGigh dose- (HDCT) with (PBPCT) |
|
|
Immune function improved with a statistically significant increase of
lymphocyte count |
[105] |
|
Bone-marrow derived stem
and progenitor cells |
Randomized, double-blind
studies |
|
Improvement of ankle-brachial index (ABI), reduction of pain, and
decreased need for amputation |
[102] |
Abbreviations:
BMCs: Mononuclear bone marrow cells, G-CS: Granulocyte colony–stimulating
factor, PBMNCs: Peripheral blood mononuclear cells, BM-MNC: Bone marrow-derived
mononuclear cells, HDCT: Chemotherapy, PBPCT: Peripheral progenitor cell
transplantation